Advisory Committee on Immunization Practices (ACIP), 56962-56963 [2022-20045]
Download as PDF
<![CDATA[
56962
Federal Register / Vol. 87, No. 179 / Friday, September 16, 2022 / Notices
Background and Brief Description
Previous surveys have focused on
private pest management firms or
agencies in a single state. The overall
capacity for publicly-funded
comprehensive tick management in the
regions of interest remains poorly
understood, especially in high
incidence areas. Data collected by
engaging vector management program
staff will inform the development of
sustainable and effective communitylevel tick management programs by
assessing the feasibility of program
components, the resources necessary to
add new functions to existing vector
management programs, and the
expected costs associated with
delivering comprehensive tick
management services. This survey will
identify robust vector management
programs with which CDC can partner
to refine guidance for the development
of comprehensive community-level tick
management programs, which can be
adapted to specific regional ecologies
and communities. Ultimately, this
survey is an important first step toward
developing a community of practice for
publicly-funded, comprehensive tick
management programs in the U.S. The
survey will lay the groundwork for
efforts to establish local entities capable
of first evaluating the efficacy of tick
control methods, and then broadly
deploying those measures proven
effective, and publicly-acceptable in
order to: (a) reduce the number of
infected ticks in the environment; and
(b) reduce human bites by infected ticks.
The primary goals of this project are
two-fold: (1) assess the current tick
management capacity and knowledge in
vector management programs that
receive public funding in the Upper
Midwest, mid-Atlantic, Northeast, and
Pacific coast states; and (2) determine
the services that vector management
program staff believe should be part of
comprehensive tick management
programs if they are developed in the
future. We also hope to identify barriers
to the development of comprehensive
tick management programs and ways
CDC can begin to address gaps.
CDC requests OMB approval for an
estimated 63 annual burden hours.
There are no costs to respondent other
than the time needed to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Form name
Public Vector Control Operators ......................................................................
Private Vector Control Operators ....................................................................
........................
........................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–20124 Filed 9–15–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0111]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), located within the
Department of Health and Human
Services (HHS), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on
October 19, 2022, from 8:30 a.m. to 5:30
p.m., EDT and October 20, 2022, from
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:43 Sep 15, 2022
Jkt 256001
8:30 a.m. to 3:20 p.m., EDT (dates and
times subject to change, see the ACIP
website for updates https://www.cdc.gov/
vaccines/acip/). The meeting
will be webcast live via the World Wide
Web. Written comments must be
received on or before October 20, 2022.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2022–
0111, by either of the following
methods.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, GA 30329–4027,
Attn: October 19–20, 2022, ACIP
Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received will be posted without change
to https://www.regulations.gov,
including any personal information
provided. For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS H24–8, Atlanta, GA 30329–
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Number of
respondents
200
100
Number of
responses per
respondent
1
1
Average
burden per
response
(in hours)
15/60
8/60
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the CDC Director and
appear on CDC immunization schedules
must be covered by applicable health
plans.
Matters To Be Considered: The agenda
will include discussions on influenza
vaccines, pneumococcal vaccine,
meningococcal vaccines, respiratory
syncytial virus vaccine, rotavirus
vaccine, dengue vaccines, adult
immunization schedule, child/
adolescent immunization schedule,
COVID–19 vaccines and Chikungunya
vaccine. Recommendation votes on
pneumococcal, adult immunization
schedule, child/adolescent
immunization schedule and COVID–19
vaccines are scheduled. A Vaccines for
E:\FR\FM\16SEN1.SGM
16SEN1
Federal Register / Vol. 87, No. 179 / Friday, September 16, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
Children (VFC) vote on COVID–19
vaccine is scheduled. Agenda items are
subject to change as priorities dictate.
For more information on the meeting
agenda visit https://www.cdc.gov/
vaccines/acip/meetings/meetingsinfo.html.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: Written
comments must be received on or before
October 20, 2022.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment during the October 19–
20, 2022, ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
acip/meetings/ no later than 11:59 p.m.
EDT, October 14, 2022, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by October 18, 2022. To accommodate
the significant interest in participation
VerDate Sep<11>2014
16:43 Sep 15, 2022
Jkt 256001
in the oral public comment session of
ACIP meetings, each speaker will be
limited to three minutes, and each
speaker may only speak once per
meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–20045 Filed 9–15–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Tick-Borne Disease
Working Group
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As required by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the Tick-Borne Disease Working
Group (TBDWG) will hold a meeting.
The meeting will be open to the public
via webcast. For this meeting, the
TBDWG will review the progress of the
Working Group.
DATES: The public can view the meeting
online via webcast on December 7, 2022
from approximately 9:00 a.m. to 5:00
p.m. ET (times are tentative and subject
to change) each day. The confirmed
times and agenda items for the meeting
will be posted on the TBDWG web page
at https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/
2022-12-07/ when this
information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the TBDWG; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Tower Building, 1101 Wootton
Parkway, Rockville, MD 20852. Email:
tickbornedisease@hhs.gov. Phone: 202–
795–7608.
SUPPLEMENTARY INFORMATION: A link to
view the webcast can be found on the
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
56963
meeting website at https://www.hhs.gov/
ash/advisory-committees/
tickbornedisease/meetings/2022-12-07/
index.html when it becomes available.
The public will have an opportunity to
present their views to the TBDWG orally
during the meeting’s public comment
session or by submitting a written
public comment. Comments should be
pertinent to the meeting discussion.
Persons who wish to provide verbal or
written public comment should review
instructions at https://www.hhs.gov/
ash/advisory-committees/
tickbornedisease/meetings/2022-12-07/
index.html and respond by midnight
November 29, 2022 ET. Verbal
comments will be limited to three
minutes each to accommodate as many
speakers as possible during the 30minute session. Written public
comments will be accessible to the
public on the TBDWG web page prior to
the meeting.
Background and Authority: The TickBorne Disease Working Group was
established on August 10, 2017, in
accordance with section 2062 of the 21st
Century Cures Act, and the Federal
Advisory Committee Act, 5 U.S.C. app.,
as amended, to provide expertise and
review federal efforts related to all tickborne diseases, to help ensure
interagency coordination and minimize
overlap, and to examine research
priorities. The TBDWG is required to
submit a report to the HHS Secretary
and Congress on their findings and any
recommendations for the federal
response to tick-borne disease every two
years.
Dated: September 8, 2022.
James J. Berger,
Designated Federal Officer, Tick-Borne
Disease Working Group, Office of Infectious
Disease and HIV/AIDS Policy.
[FR Doc. 2022–20092 Filed 9–15–22; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–New]
Agency Information Collection
Request; 60-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
SUMMARY:
E:\FR\FM\16SEN1.SGM
16SEN1
]]>Agencies
[Federal Register Volume 87, Number 179 (Friday, September 16, 2022)]
[Notices]
[Pages 56962-56963]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20045]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0111]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), located within the
Department of Health and Human Services (HHS), announces the following
meeting of the Advisory Committee on Immunization Practices (ACIP).
This meeting is open to the public. Time will be available for public
comment.
DATES: The meeting will be held on October 19, 2022, from 8:30 a.m. to
5:30 p.m., EDT and October 20, 2022, from 8:30 a.m. to 3:20 p.m., EDT
(dates and times subject to change, see the ACIP website for updates
https://www.cdc.gov/vaccines/acip/). The meeting will be
webcast live via the World Wide Web. Written comments must be received
on or before October 20, 2022.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0111, by either of the following methods.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027, Attn: October 19-20,
2022, ACIP Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the CDC Director and appear on CDC immunization
schedules must be covered by applicable health plans.
Matters To Be Considered: The agenda will include discussions on
influenza vaccines, pneumococcal vaccine, meningococcal vaccines,
respiratory syncytial virus vaccine, rotavirus vaccine, dengue
vaccines, adult immunization schedule, child/adolescent immunization
schedule, COVID-19 vaccines and Chikungunya vaccine. Recommendation
votes on pneumococcal, adult immunization schedule, child/adolescent
immunization schedule and COVID-19 vaccines are scheduled. A Vaccines
for
[[Page 56963]]
Children (VFC) vote on COVID-19 vaccine is scheduled. Agenda items are
subject to change as priorities dictate. For more information on the
meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: Written comments must be received on or
before October 20, 2022.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment during the October 19-20, 2022, ACIP meeting
must submit a request at https://www.cdc.gov/vaccines/acip/meetings/ no
later than 11:59 p.m. EDT, October 14, 2022, according to the
instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by October 18, 2022. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to three minutes, and each
speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-20045 Filed 9-15-22; 8:45 am]
BILLING CODE 4163-18-P
